Search
OraSure Technologies Inc
OSURAdd to Watchlist
3.000USD
+0.050+1.69%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
206.55MMarket Cap
LossP/E TTM
More Details of OraSure Technologies Inc Company
OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.
OraSure Technologies Inc Info
Ticker SymbolOSUR
Company nameOraSure Technologies Inc
IPO dateNov 17, 1986
CEOEglinton Manner (Carrie)
Number of employees501
Security typeOrdinary Share
Fiscal year-endNov 17
Address220 E First St
CityBETHLEHEM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code18015
Phone15036416115
Websitehttps://www.orasure.com/
Ticker SymbolOSUR
IPO dateNov 17, 1986
CEOEglinton Manner (Carrie)
Company Executives of OraSure Technologies Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
589.56K
--
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
163.61K
--
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
--
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
--
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+52.26%
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Jason Plagman
Mr. Jason Plagman
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Mr. Robert W. Mcmahon
Mr. Robert W. Mcmahon
Independent Director
Independent Director
--
--
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Steven K. (Steve) Boyd
Mr. Steven K. (Steve) Boyd
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
589.56K
--
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
163.61K
--
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
--
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
--
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+52.26%
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Net product and services revenues - HIV
49.80M
43.30%
Net product and services revenues - Microbiome
38.36M
33.35%
Net product and services revenues - HCV
13.76M
11.96%
Other revenues - Other non Product revenues
5.97M
5.19%
Net product and services revenues - Other Products revenue
4.65M
4.04%
Other
2.49M
2.16%
By RegionUSD
Name
Revenue
Proportion
United States
78.25M
68.03%
Africa (Region)
23.99M
20.86%
Europe
7.39M
6.43%
Other Regions
5.38M
4.68%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Net product and services revenues - HIV
49.80M
43.30%
Net product and services revenues - Microbiome
38.36M
33.35%
Net product and services revenues - HCV
13.76M
11.96%
Other revenues - Other non Product revenues
5.97M
5.19%
Net product and services revenues - Other Products revenue
4.65M
4.04%
Other
2.49M
2.16%
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Private Management Group, Inc.
7.88%
BlackRock Institutional Trust Company, N.A.
7.77%
Neuberger Berman, LLC
5.79%
Altai Capital Management, L.P.
5.25%
Vanguard Capital Management, LLC
4.40%
Other
68.92%
Shareholders
Shareholders
Proportion
Private Management Group, Inc.
7.88%
BlackRock Institutional Trust Company, N.A.
7.77%
Neuberger Berman, LLC
5.79%
Altai Capital Management, L.P.
5.25%
Vanguard Capital Management, LLC
4.40%
Other
68.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.78%
Investment Advisor/Hedge Fund
26.42%
Hedge Fund
22.56%
Individual Investor
6.31%
Research Firm
2.55%
Pension Fund
0.44%
Bank and Trust
0.21%
Venture Capital
0.18%
Insurance Company
0.03%
Other
4.52%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
436
65.49M
91.21%
-10.07M
2025Q4
443
65.20M
90.89%
-16.92M
2025Q3
451
66.91M
93.28%
-15.50M
2025Q2
473
72.08M
98.55%
-16.70M
2025Q1
483
70.23M
93.78%
-12.52M
2024Q4
475
70.81M
94.94%
-10.37M
2024Q3
471
70.30M
94.28%
-10.80M
2024Q2
477
73.05M
98.74%
-8.54M
2024Q1
473
74.45M
97.36%
-5.59M
2023Q4
464
73.29M
99.74%
-5.62M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Private Management Group, Inc.
5.40M
7.81%
-21.07K
-0.39%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
5.35M
7.74%
-250.87K
-4.48%
Dec 31, 2025
Neuberger Berman, LLC
3.98M
5.76%
-218.98K
-5.21%
Dec 31, 2025
Altai Capital Management, L.P.
3.61M
5.23%
-127.00K
-3.39%
Mar 17, 2026
Dimensional Fund Advisors, L.P.
3.26M
4.71%
-377.67K
-10.39%
Dec 31, 2025
Systematic Financial Management, L.P.
2.48M
3.58%
-44.87K
-1.78%
Dec 31, 2025
Eglinton (Manner Carrie)
2.19M
3.17%
+360.05K
+19.67%
Mar 20, 2026
Renaissance Technologies LLC
2.15M
3.1%
-116.10K
-5.13%
Dec 31, 2025
Acadian Asset Management LLC
2.02M
2.93%
-102.81K
-4.84%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.44%
iShares US Small Cap Value Factor ETF
0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.05%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Avantis US Small Cap Equity ETF
0.02%
WisdomTree US SmallCap Fund
0.02%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
DFA Dimensional US Small Cap Value ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.44%
iShares US Small Cap Value Factor ETF
Proportion0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proportion0.05%
iShares Micro-Cap ETF
Proportion0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.02%
WisdomTree US SmallCap Fund
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
DFA Dimensional US Small Cap Value ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
